Articles published by Marinus Pharmaceuticals
![](https://mms.businesswire.com/media/20221107006134/en/1628497/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Proposed Public Offering
November 07, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20221107005871/en/1627836/5/marinus-color.jpg)
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
November 07, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20221031005137/en/1618147/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20221025005036/en/1610243/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20221014005076/en/1601996/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 14, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20221011005478/en/1597687/5/marinus-color_%286%29.jpg)
Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings
October 11, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220922005179/en/1579655/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20220909005404/en/1567095/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220829005076/en/1554675/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million
August 29, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220812005004/en/1540839/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 12, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220811005003/en/1536036/5/marinus-color.jpg)
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 11, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220722005348/en/1526422/21/ZTALMYone_%28002%29.jpg)
![](https://mms.businesswire.com/media/20220715005330/en/1515094/5/marinus-color_%282%29.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 15, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220714005118/en/1512930/5/marinus-color_%282%29.jpg)
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
July 14, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220713005199/en/1511930/5/marinus-color_%282%29.jpg)
![](https://mms.businesswire.com/media/20220608005202/en/1479577/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20220603005422/en/1476121/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220512005992/en/1454217/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20220510006268/en/1450429/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 10, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220505005002/en/1433693/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
May 05, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220420005372/en/1425900/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20220418005446/en/1423547/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 18, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220413006051/en/1421013/5/marinus-color_%284%29.jpg)
![](https://mms.businesswire.com/media/20220331005599/en/1406808/5/marinus-color_%283%29.jpg)
![](https://mms.businesswire.com/media/20220321005312/en/1395243/5/marinus-color_%282%29.jpg)
![](https://mms.businesswire.com/media/20220318005282/en/1394489/5/marinus-color_%281%29.jpg)
![](https://mms.businesswire.com/media/20220222005974/en/1367268/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20220216005461/en/1361316/5/marinus-color.jpg)
![](https://mms.businesswire.com/media/20220210005807/en/1356391/5/marinus-color.jpg)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 10, 2022
Via Business Wire
Tickers
MRNS
![](https://mms.businesswire.com/media/20220203005292/en/1348229/5/marinus-color.jpg)
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
February 03, 2022
Via Business Wire
Tickers
MRNS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.